Crossref
Real‐World Outcomes of Gemcitabine Plus Nab‐Paclitaxel Versus Modified FOLFIRINOX in Advanced Pancreatic Cancer
Asia-Pacific Journal of Clinical Oncology · 2026-11 · 22 (S6) · 12-12
DOI: 10.1111/ajco.70227 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, online erschienen am 19.11.2026.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). Real‐World Outcomes of Gemcitabine Plus Nab‐Paclitaxel Versus Modified FOLFIRINOX in Advanced Pancreatic Cancer. Asia-Pacific Journal of Clinical Oncology, 22(S6), 12-12. https://doi.org/10.1111/ajco.70227
Vancouver
Real‐World Outcomes of Gemcitabine Plus Nab‐Paclitaxel Versus Modified FOLFIRINOX in Advanced Pancreatic Cancer. Asia-Pacific Journal of Clinical Oncology. 2026;22(S6):12-12. doi:10.1111/ajco.70227
BibTeX
@article{euvimed2026,
title = {Real‐World Outcomes of Gemcitabine Plus Nab‐Paclitaxel Versus Modified FOLFIRINOX in Advanced Pancreatic Cancer},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2026},
volume = {22},
number = {S6},
pages = {12--12},
doi = {10.1111/ajco.70227}
}
EUVIMED